COPD

Chronic Obstructive Pulmonary Disease (COPD) is a term commonly used for a group of lung problems

including but not limited to emphysema, chronic bronchitis, and refractory asthma characterized by severe breathing difficulty and coughing.
It is commonly understood that tobacco smoke is the principal cause for the development of COPD. Both active as well as passive smokers are at higher risk of COPD, along with people who have long term exposure to air pollutants.

Apart from the main cause, some of the secondary risk factors are family history, preterm birth, and asthma. Chronic Obstructive Pulmonary Disease changes the respiratory system by damaging the walls of the air sacs as they thicken and become inflamed and lose elasticity. Thus, with COPD, the flow of oxygenated air is obstructed resulting in deprivation of oxygen and subsequent complications.

Current treatment approaches do not reverse the damage associated with the disease or interrupt the progression completely and are directed at relieving symptoms, slowing progression, and preventing complications.

Treatment of COPD at Cellebration Wellness

At Cellebration, we have mastered the technology for isolating the maximum number of viable stem cells from either an autologous source from the patient’s own body or allogeneic from a matched donor to treat patients with COPD.

Stem cell treatment for COPD involves administration of concentrated cells in the targeted area to form colonies, adapt the properties of resident stem cells, and initiate some of the lost functions that have been compromised by the disease or injury.

These cells are administered through one of two methods after a considerable analysis of the patient’s unique history.

Stem cell treatment involves administration of concentrated cells in the targeted area, wherein they can colonize in the damaged area, adapt the properties of resident stem cells, and initiate some of the lost functions that have been compromised by the disease or injury.

Research data suggests that the differentiation of stem cells into cardiomyogenic lineage are known to express angiogenic properties thereby increasing the network of blood vessels, maximizing the flow of blood, and improving heart efficiency.

The mesenchymal stem cells isolated from both allogenic and autologous sources are known to differentiate into myogenic lineage, thus improving the cardiac pumping. These cells are administered through one of two methods after a considerably analysis of each patient’s unique history.

Local Administration

In this delivery mode, cells are infused into the peripheral veins to expand blood volumes in the system, to ensure that the maximum number of cells are reaching the targeted area.

Intravenous Administration

In this delivery mode, cells are infused into the peripheral veins to expand blood volumes in the system, to ensure that the maximum number of cells are reaching the targeted area.

Once infused back into the body, these cells can be repopulated at the damaged parts of the organ. Through their strong paracrine effects, they differentiate into lost or damaged alveolar epithelial cells of the air sacs. With our standardized, broad based and holistic approach, it is now possible to obtain noticeable improvements in patients with COPD for symptoms as well as their functional abilities.